BACKGROUND: Endocrine therapy (ET) is recommended for estrogen receptor (ER)-positive breast cancer (BC), though its benefit in ER-low (1-10%) disease remains uncertain. Using the National Cancer Database (NCDB) from 2018 to 2020, we previously found that ET omission was associated with worse survival among 7018 patients with ER-low BC treated with (neo)adjuvant chemotherapy, with 586 deaths observed (Choong et al.). Herein, we evaluate ET omission and survival in an expanded NCDB cohort.PATIENTS AND METHODS: Female patients with stage I-III ER-low BC diagnosed between 2018 and 2023 and treated with neoadjuvant chemotherapy (NAC) and/or adjuvant chemotherapy were identified. Trends in ET use were assessed from 2018 to 2023, and overall survival (OS) was analyzed for patients diagnosed from 2018 to 2022. Kaplan-Meier methods estimated OS, and multivariable Cox regression evaluated associations between ET omission and mortality.RESULTS: Among 12,983 patients, 8658 received NAC (53% achieved pathologic complete response [pCR]) and 4325 received adjuvant chemotherapy alone. ET use declined significantly over time (62% in 2018 versus 33% in 2023, p < 0.001), with the greatest decline among NAC-treated patients. OS analysis included 11,136 patients (median follow-up 3.4 years; 1137 deaths). ET omission was associated with worse OS (aHR 1.24, p < 0.001), particularly in patients with residual disease (RD) after NAC (aHR 1.23, p = 0.01). ET omission was associated with worse survival in both ER 1-5% and ER 6-10% subgroups.CONCLUSIONS: ET use in ER-low BC treated with chemotherapy is declining. ET omission in ER-low BC treated with NAC with residual disease was associated with significantly worse overall survival.
MG
Dr. Matthew Goetz
Infectious Disease · Antibiotic StewardshipVA Greater Los Angeles Healthcare Systemmatthewgoetz